See more : Henkel AG & Co. KGaA (HENOF) Income Statement Analysis – Financial Results
Complete financial analysis of NOXXON Pharma N.V. (ALNOX.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NOXXON Pharma N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- SNT Motiv Co., Ltd. (064960.KS) Income Statement Analysis – Financial Results
- Ookami Limited (OOK.AX) Income Statement Analysis – Financial Results
- Sarla Performance Fibers Limited (SARLAPOLY.NS) Income Statement Analysis – Financial Results
- Minerva Intelligence Inc. (MVAI.V) Income Statement Analysis – Financial Results
- G.A. Holdings Limited (8126.HK) Income Statement Analysis – Financial Results
NOXXON Pharma N.V. (ALNOX.PA)
About NOXXON Pharma N.V.
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00K | 43.00K | 25.00K |
| Cost of Revenue | 0.00 | 0.00 | 1.03M | 982.00K | 959.00K | 1.46M | 2.64M | 3.68M |
| Gross Profit | 0.00 | 0.00 | -1.03M | -982.00K | -959.00K | -1.38M | -2.60M | -3.65M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,657.83% | -6,044.19% | -14,612.00% |
| Research & Development | 10.66M | 4.02M | 496.00K | 479.00K | 402.00K | 1.03M | 906.00K | 1.50M |
| General & Administrative | 1.27M | 912.00K | 1.32M | 1.29M | 1.13M | 2.30M | 4.97M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 263.00K | 307.00K | 409.00K | 149.00K |
| SG&A | 1.27M | 912.00K | 1.32M | 1.29M | 1.40M | 2.60M | 5.38M | 1.56M |
| Other Expenses | 1.53M | 822.00K | 1.10M | 1.57M | 1.97M | 3.40M | 5.40M | 6.45M |
| Operating Expenses | 13.45M | 5.75M | 2.92M | 3.34M | 3.77M | 7.03M | 11.68M | 9.50M |
| Cost & Expenses | 13.45M | 5.75M | 3.94M | 4.32M | 4.73M | 8.49M | 14.32M | 13.18M |
| Interest Income | 319.00K | 418.00K | 3.09M | 388.00K | 1.02M | 1.00K | 0.00 | 3.00K |
| Interest Expense | 1.50M | 5.06M | 3.00K | 6.76M | 1.68M | 2.13M | 1.29M | 632.00K |
| Depreciation & Amortization | 66.00K | 63.00K | 47.00K | 23.00K | 29.00K | 340.00K | 218.00K | 279.00K |
| EBITDA | -12.88M | -5.29M | -810.00K | -3.95M | -3.68M | -8.25M | -14.61M | -12.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,943.37% | -33,981.40% | -51,536.00% |
| Operating Income | -12.95M | -5.35M | -857.00K | -3.98M | -3.71M | -8.59M | -14.83M | -13.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -10,353.01% | -34,488.37% | -52,652.00% |
| Total Other Income/Expenses | -1.51M | -5.06M | -3.00K | -6.76M | -1.68M | -2.13M | -1.29M | -632.00K |
| Income Before Tax | -14.45M | -10.41M | -860.00K | -10.74M | -5.39M | -10.73M | -16.12M | -13.80M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,921.69% | -37,497.67% | -55,180.00% |
| Income Tax Expense | 1.00K | 5.06M | 1.00K | 1.00K | 1.00K | 27.00K | -22.00K | 3.00K |
| Net Income | -14.45M | -15.46M | -861.00K | -10.74M | -5.39M | -10.75M | -16.10M | -13.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,954.22% | -37,446.51% | -55,192.00% |
| EPS | -45.99 | -47.78 | -7.72 | -269.86 | -253.81 | -536.18 | -802.97 | -688.08 |
| EPS Diluted | -45.99 | -47.78 | -7.72 | -269.86 | -253.81 | -536.18 | -802.97 | -688.08 |
| Weighted Avg Shares Out | 314.27K | 323.59K | 111.58K | 39.79K | 21.24K | 20.05K | 20.05K | 20.05K |
| Weighted Avg Shares Out (Dil) | 314.27K | 323.59K | 111.58K | 39.79K | 21.24K | 20.05K | 20.05K | 20.05K |
Source: https://incomestatements.info
Category: Stock Reports